


ARC 2300N2
Response to Restriction Requirement



1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail under 37 CFR §1.8 in an envelope addressed to: Honorable Commissioner for Patents and Trademarks, Washington, D.C. 20231.

Date:

March 27, 2003

By:

Yolanda F. Kepner
Yolanda F. Kepner

TECH CENTER 12012900
APR 8 2003

RECEIVED
#6/B
3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sonya Merrill et al
Serial No.: 09/905,526
Filed: July 13, 2001
For: HYDROMORPHONE
THERAPY

Group Art Unit: 1617

Examiner: SHARAREH, S.J.

Amendment in Response to
Restriction Requirement
Under 35 U.S.C § 121

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

AMENDMENT

Sir/Madam:

This correspondence is in response to the Office Action mailed October 17, 2002, regarding the above-entitled application for which the time to respond is through April 17, 2003 upon acceptance of Applicants' petition for extension of time. This amendment is in presented in response to Restriction Requirement contained therein. Reconsideration of this application is requested.

Please amend the application as follows.

IN THE SPECIFICATION

On page 1, line 1, in the ~~Title~~, please at the beginning of the lines in the title --
-ORAL DOSAGE FORMS FOR---- before "HYDROMORPHONE THERAPY," to give
the new title ----ORAL DOSAGE FORMS FOR HYDROMORPHONE THERAPY ----.